Work

Figure S2 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors

Year: 2023

Type: other

Abstract: CEA response over time in a 47-year-old patient with GEC responding to telisotuzumab

DOI: 10.1158/1535-7163.22518672.v1

Authors: John H. Strickler, Patricia LoRusso, Ravi Salgia, Yoon-Koo Kang, Chia Jui Yen, Chia-Chi Lin, Peter Ansell, Monica Motwani, Shekman Wong, Huibin Yue, Lan Wang, Edward Reilly, Daniel Afar, Louie Naumovski, Ramesh K. Ramanathan

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362487838

Cites:

Cited by:

Related to: 10